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Abstract
The aim of this study was to evaluate the therapeutic efficacy of biomimetic zinc-containing tricalcium phosphate (ZnTCP)
produced by hydrothermally converting calcium carbonate exoskeletons from foraminifera, in the treatment of osteoporotic
mice. X-Ray powder diffraction showed crystallographic structures matching JCPDS profile for tricalcium phosphate. Mass
spectroscopy used to calculate total composition amount showed similar amount of calcium (56104 mg/g) and phosphate
(46104 ppm) after conversion and the presence of zinc (5.186103 mg/g). In vitro zinc release showed no release in PBS buffer
and,1% zinc release in 7 days. In vivo evaluation was done in ovariectomized mice by implanting the ZnTCP samples in the
soft tissues near the right femur bone for four weeks. Thirty ddY mice (5 weeks old, average weight of 21 g) were divided
into six experimental groups (normal, sham, OVX, b-TCP, ZnTCP and direct injection of zinc). CT images were taken every
two weeks where the bone mineral density (BMD) and bone mineral content (BMC) were calculated by software based on
CT images. The ZnTCP group exhibits cortical and cancellous bone growth of 45% and 20% respectively. While sham, OVX
and b-TCP suffered from bone loss. A correlation was made between the significant body weight increase in ZnTCP with the
significant increase in plasma zinc level compared with OVX. The presented results indicate that biomimetic ZnTCP were
effective in preventing and treating bone loss in osteoporotic mice model.
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Introduction
The development of advanced and innovative drug delivery
systems has over the years reached a paucity in which a
biomimetic approach can offer new potentials and inspire future
advancements in this area. Since the development of hydrothermal
conversion of calcium carbonate from coral exoskeletons to
calcium phosphate by [1], theses materials have been used
successful in various bone augmentation applications. Our group
has shown that fossilized foraminifera, available commercially, can
be use as a drug carrier for antibiotics [2], bisphosphonate [3] and
simvastatin [4].
Foraminifera possess a naturally uniform and interconnected
porous network allowing consistent drug loading and release.
Through hydrothermal conversion this unique structure can be
preserve while transforming the material to tricalcium phosphate
[5]. The present study seeks to combine a biomimetic material
coupled with synthetic modifications to achieve a therapeutically
relevant delivery system in the treatment of osteoporotic mice.
Over the past years, significant interest has been vested on the
modifications of biomaterials by incorporating inorganic dopants
such as magnesium and strontium for there ability to stimulate
osteoblasts while inhibiting osteoclasts and increasing mechanical
properties of the bone [6–9]. While these have been used with
degrees of success for various bone repair applications, one key
biological element remains vastly overlooked in comparison. Zinc,
a key element responsible in the regulation of cells, has shown to
possess stimulatory effects on osteoblast bioactivity and bone
formation [10–12]. In the past several years, different types of Zn-
TCP formulations have been developed. Injectable Zn-TCP
powders have shown to increase the BMD in osteoporotic rats
[13], injectable Zn-TCP nanoparticles on jawbone bone mineral
density have shown increased bone formation and mechanical
strengths in osteoporotic rats [14] and in rabbit femora it was
shown that over 50% new bone was formed [12]. More recently,
studies have shown a relationship between osteoporosis and zinc
deficiency in particularly in the elderlies [15]. However as a
resorbable ceramic, TCP possess a higher solubility rate both
in vitro and in vivo. If TCP degrades too rapidly, this may result in
zinc ion released at high levels causing severe toxicity reactions
[12,16]. Furthermore, most Zn-TCP ceramic require sintering at
high temperatures which can degrade the material’s mechanical
properties and can be challenging for large-scale productions.
In this study, a new novel zinc delivery system is developed
based on using foraminifera with low-temperature hydrothermal
conversion to produce Zn-TCP which was than inserted into the
soft tissues near the femur bone in a zinc-deficient osteoporotic
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mice model. While different systems of zinc containing tricalcium
phosphate have been developed over the years, this study to the
best knowledge of the authors is the first demonstration of using a
biomimetic material as a carrier for zinc. This study will
investigate if biomimetic Zn-TCP is able to induce beneficial
pharmacological effect in treating osteoporotic mice.
Materials and Methods
Hydrothermal Synthesis and Characterization of Zn-TCP
Material
Calcium carbonate samples from foraminifera were purchased
commercially (Business Support Okinawa Co. Ltd., Japan) and no
specific permits or licenses were required for the described study.
The samples were cleansed in sodium hydrochlorite for 20 mins
and dried at 40uC for 2 hours to remove any residual organics.
The hydrothermal conversion was performed by immersing
300 mg of foraminifera with aqueous diammonium hydrogenpho-
sphate [(NH4)2(HPO4)] (Wako Chemical Co., Tokyo, Japan),
adjusted to yield Ca/P molar ratios of 1.5 to produce b-TCP and
30 mg of zinc nitrate hexahydrate (Zn(NO3)2?6H20, Wako
Chemical Co., Tokyo, Japan) and heated to 220uC for 48 hours
in a pressure vessel. A schematic diagram of the experimental
design is shown in Figure 1. Crystallographic profiles of the
samples before and after hydrothermal conversion were measured
by X-ray diffraction (XRD) (RINT- Ultima-III, Rigaku Co.,
Japan; CuKa radiation, 40 kV, 40 mA) and matched with JCPDS
database. The surface morphological features of the Zn-TCP
samples were observed by scanning electron microscopy (SEM)
(JEOL JSM-7600F, Field Emission SEM, 10KV) before and after
implantation. The excised samples were treated in 10% formal-
dehyde for 24 hours at 2uC and dehydrated in 60, 70, 80, 90 and
100% alcohol and allowed to dry before observing under SEM.
For quantifying the chemical composition of the samples,
approximately 0.005 g of sample was digested with 0.25 mL of
HNO3. Once the digestion was completed the sample volume was
made up to 5 mL. The samples underwent a further 1:100 dilution
with a 1% nitric acid solution before ICP-MS analysis. Samples
were diluted further in nitric acid as required. An Agilent
Technologies 7500ce series ICP-MS was used with sample
introduction via a micromist concentric nebuliser (Glass expan-
sion) and a Scott type double pass spray chamber cooled to 2uC.
The sample solution and the spray chamber waste were carried
with the aid of a peristaltic pump. The ICP operating parameters
and the lens conditions were selected to maximise the sensitivity of
a 1% HNO3:HCl solution containing 1 ng/ml of Li, Co, Y, Ce
and Tl. Helium was added into the octopole reaction cell to reduce
interferences. Calibration curves were constructed and the results
analysed using Agilent Technologies Masshunter software. Mg, P,
Ca, Zn and Sr stock solutions were obtained from Choice
Analytical, Thornleigh, Australia. Baseline nitric acid (HNO3) was
purchased from Seastar chemicals, Sidney, Canada. Calibration
standards were prepared in 1% nitric acid. Samples were spiked
with nitric acid to a level of 1% to matrix match the calibration
standards.
Measurement of in vitro Zinc Release
The zinc release rate was measured in phosphate buffer saline
(PBS) and in acetate buffer (pH 4.5) prepared in accordance with
Japanese Pharmacopeia. One ZnTCP sample was immersed in
10 mL buffer solution regulated thermostatically in a 37.060.1uC
water bath shaken at 100 rpm. After every 24 hours for 7 days, the
entire dissolution medium was collected and replaced with fresh
buffer solution. Zinc concentration from the collected medium was
measured by zinc detection kit (Metallo Assay Zinc LS, AKJ
Global Technology Co. Ltd., Japan) at 560 nm using a UV-VIS
spectrophotometer (Type UV160, Shimadzu Co., Japan).
Animal Surgery and Procedures
Animal surgery and care was performed in accordance to the
Animal Care Committee guidelines and approval from the Animal
Ethics Committee at the Research Institute of Pharmaceutical
Sciences, Musashino University. Thirty mice were assigned
randomly into six groups (n = 5) as outlined in Table 1: 1) normal,
2) sham, 3) ovariectomized (OVX), 4) beta-tricalcium phosphate
(b-TCP), 5) zinc-tricalcium phosphate (Zn-TCP) and 6) direct
injection of zinc at approximately same concentration as Zn-TCP
group (DI/ZN). Ovariectomy (OVX) was performed on thirty
female ddY mice averaging 21 g in weight (Clea Co., Japan) under
anaesthesia by intraperitoneal administration of sodium pento-
barbital (0.1 mL/kg). During this time and for the duration of the
experiment, groups 2–6 were fed a special diet (calcium, vitamin D
and zinc deficient, Clea Co. Ltd, Japan) to induce and maintain
the osteoporotic condition in the mice. Group1 (normal) received a
normal diet without ovariectomy. Two weeks after ovariectomy,
the mice were anesthetized by intraperitoneal administration of
sodium pentobarbital (0.1 mL/kg) where five samples (15 mg)
were implanted into the soft tissues near the right femur of the
mice. After 4 weeks, the mice were euthanized by overdose of
diethyl ether anesthesia, and the implanted samples and the
femurs were excised for further analysis.
In vivo Analysis
Bone mineral density (BMD) and bone mineral content (BMC)
were calculated by X-Ray CT (LCT-200A, ALOKA, Japan)
images and analyze in system software (Latheta, ALOKA, Japan)
based on CT images taken every two weeks. The measurement of
zinc concentration was based on blood plasma collected after the
mice were euthanized after four-weeks. Zinc concentration in the
plasma was determined by a zinc detection kit (Metallo Assay Zinc
LS, AKJ Global Technology Co. Ltd., Japan) according to
Figure 1. An outline of the experimental protocol for the
production of Zn-TCP and procedure for the animal experi-
ment.
doi:10.1371/journal.pone.0071821.g001
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manufacturer’s protocols and measuring at 560 nm using a UV-
VIS spectrophotometer (Type UV160, Shimadzu Co., Japan).
Statistical Analysis
All data were examined based on five different measurement
values and presented as mean 6 standard deviation. Repeated
measurement analysis of variance (ANOVA) was used to
determine significant differences among the groups and a p-value
,0.05 was considered significant.
Results
Characterization of Zn-TCP Delivery System
Zn-TCP material was produced by hydrothermally converting
calcium carbonate from foraminifera. A more detailed physico-
chemical characterization was performed in a previous study [17].
Figure 2 shows the X-ray powder diffraction profile of the
foraminifera, b-TCP and Zn-TCP samples. The diffraction patterns
match JCPDS 5-0586 for calcium carbonate and JCPDS 9-169
peaks corresponding to b-TCP. There was no significant
difference with the Zn-TCP peak patterns, which suggest that
the zinc was successfully incorporated by substituting in place for
calcium. A detailed overview of the compositional amount of
calcium, phosphate and zinc from the samples are outlined in
Table 2. The amount of calcium in b-TCP and Zn-TCP was
calculated to be 4.456104 and 5.106104 mg/g and phosphate,
4.106104 and 3.756104 mg/g respectively. The b-TCP sample
contained no amount of zinc while Zn-TCP had 5.186103 mg/g,
which confirms that the conversion process was successful.
Evaluation of in vitro Release of Zinc
The release of zinc from Zn-TCP in acetate and PBS buffer are
shown in Figure 3 (a). There was an initial burst release of zinc
during the first 24 hours in acetate buffer solution before the
release reached a constant concentration around 150–160 mg/dL.
Taking into account the average zinc concentration in each Zn-
TCP sample, this only accounts for ,1% of the total zinc
composition. This suggests that the majority of zinc are still within
the material. No zinc release was observed in the PBS buffer
solution. The zinc release rate was rapid initially in acetate buffer,
suggesting that zinc was first released from the surface as the
material slowly degrades and subsequent release through the
macro- and micro pores. Therefore the zinc release from porous










where Mt is the amount of drug release after time t, A is the matrix
surface area, D is the diffusion coefficient of the drug, Cs is the
solubility, Cd is the concentration of the drug in the matrix, t is the
tortuosity and e is the porosity of the matrix. The in vitro zinc
release profile in acetate buffer was plotted with zinc concentration
against the square root of time as shown in Figure 3 (b). The plot
shows two phases of zinc release. The initial burst release was due
to conventional release of zinc from the surface of the ZnTCP as
illustrated by slope (1). The second order release profile shows a
linear slope (2) in the Higuchi plot suggesting that the release of
zinc from the matrix material is based on a drug diffusion process
through the macro- and micro pores of ZnTCP. The release rate
constants based on the two slopes of the plots were calculated to
be: slope (1) 25 mg/d1/2 and slope (2) 6 mg/d1/2.
Table 1. Assignment of experimental groups and treatments.
Group Diet Type Treatment Group Acronym
1 (Control) Normal food Normal mice None Normal
2 (Control) Special* OVX mice Sham Sham
3 (Control) Special* OVX mice Ovariectomized OVX
4 Special* OVX mice b-TCP material implanted b-TCP
5 Special* OVX mice Zn-TCP material implanted Zn-TCP
6 Special* OVX mice Direct injection of equal amount of zinc to Zn-TCP DI/ZN
*Special diet refers to calcium, vitamin D, magnesium and zinc deficient diet.
doi:10.1371/journal.pone.0071821.t001
Figure 2. The XRD pattern corresponding to foraminifera, b-TCP
and Zn-TCP showing peaks matching calcium carbonate
(JCPDS 5-0586) and tricalcium phosphate (JCPDS 9-169).
doi:10.1371/journal.pone.0071821.g002
Table 2. Chemical composition of sample material.
Calcium Phosphate Zinc
b-TCP 4.45610461.26103 4.1610465.36103 0
Zn-TCP 5610464.76103 3.75610461.46103 5.186103636102
doi:10.1371/journal.pone.0071821.t002
Zn-TCP in the Treatment of Osteoporotic Mice
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Examination of Zn-TCP Structural Morphology
Figure 4 shows SEM images of the structural morphology of b-
TCP [(b),(d)] and Zn-TCP [(a),(c)] before and after implantation in
OVX. It can be seen from the figures that after 4 weeks the
structure of both samples remained unchanged except for the
growth of fibroblastic tissues around both the b-TCP and Zn-TCP
sample (c). This indicates that the amount of zinc released is not
detrimental to the surrounding tissues.
Effect of Zn-TCP and Direct Injection of Zinc on
Osteoporotic Mice
Direct injection of zinc (DI/ZN), at approximately the same
concentration (20 mg/week) as Zn-TCP, was injected in the soft
tissues near the right femur of the osteoporotic mice as a way of
comparing the two-treatment method. Unfortunately, all the mice
in the DI/ZN group did not survive past week 2 and as such no
analysis was performed for this group in the subsequent analysis.
Observation of the mice (Figure 5) in (a) Zn-TCP and (b) DI/ZN
group showed significant deterioration of the soft tissue at the zinc
Figure 3. The in vitro (a) zinc release in acetate buffer (70%) and PBS (0%) over 7 days and (b) the complementing Higuchi plot
showing two phases of zinc release: surface zinc release (slope 1) and drug diffusion release from the matrix material (slope 2).
doi:10.1371/journal.pone.0071821.g003
Figure 4. SEM images showing the morphological structure of Zn-TCP (a) before, (c) after and b-TCP (b) before, (d) after 4 week
implantation in OVX mice. From the images there is no significant structural change to the surface morphology with the exception of tissue
growth around the sample material.
doi:10.1371/journal.pone.0071821.g004
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injection site of the DI/ZN group. This rendered the mice the
inability to possess normal function of its right leg. Using the CT
images, a complete 3D reconstruction of the femur was made to
observe the position of the Zn-TCP samples in reference to the
femur bone. Figure 5 (c) show that the Zn-TCP was indeed placed
near the femur bone and Figure 5 (d) showed that how the femur
bone was pushed together from the soft tissue deterioration. This
serious side effect associated with highly localized zinc concentra-
tion was not observed in the Zn-TCP group.
Effect of B-TCP and Zn-TCP on Mice Body Weight
The body weights of the mice were monitored and recorded as
this directly correlates to the amount of bone and soft tissues from
the mice. The application of Zn-TCP to the osteoporotic mice led
to a continuous and significant increase in body weight after 4
weeks to the same level as normal healthy mice [Figure 6 (a)]. In
contrast, no significant increase in body weight was observed for
the mice in sham, OVX and b-TCP groups.
Effect of Zn-TCP on Plasma Zn Level of Osteoporotic Mice
Plasma zinc levels collected from the osteoporotic mice after 4-
weeks [Figure 6 (b)] showed decreasing level of zinc concentration
in the order of normal, sham, OVX, b-TCP and Zn-TCP. There
was a significant decrease in zinc concentration between normal,
sham and OVX compared with b-TCP and Zn-TCP. It should be
noted that the mice were fed with a zinc deficient diet to observe
the changes in the plasma zinc level.
Effect of Zn-TCP on BMC and BMD
The percentage increase/decrease in the right femur cortical
and cancellous BMC is shown in Figure 7 (a) and (b) respectively.
b-TCP and Zn-TCP groups showed 40 and 45% increase
respectively in cortical bone mass, which is significantly different
compared with the OVX control group. The BMC of the
cancellous bone displayed significant changes between the
experimental groups. Sham, OVX and b-TCP exhibited 12, 22
and 30% reduction in cancellous BMC over the 4-week period
while normal and Zn-TCP groups had 5 and 20% increase during
the same period. Zn-TCP showed significantly higher increase in
cancellous BMC compared with all experimental groups. Figure 7
(c) and (d) show the right femur BMD of the cortical and
cancellous bone. The BMD of the cortical bone did not show any
significant changes while the BMD from the cancellous bone of the
normal group displayed significant increase with all the experi-
mental groups during week 2 and week 4. The cancellous bone
BMD from sham, OVX, b-TCP and Zn-TCP group remained
constant during the experimental period.
Figure 5. Image showing the difference from macroscopic observation between (a) implanted Zn-TCP and (b) direct injection of
zinc exhibiting severe muscle deterioration. Computer reconstruction of the femur bone showed (c) the Zn-TCP placed near the femur bone
and (d) the inhibition of bone extension due to the muscle breakdown.
doi:10.1371/journal.pone.0071821.g005
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Figure 6. From these results a close relationship between the (a) the mice body weight and (b) plasma zinc level was observed. Zn-
TCP group showed a significantly higher body weight with increased plasma zinc level.
doi:10.1371/journal.pone.0071821.g006
Figure 7. Based on the CT scans, the cortical and cancellous bone BMC and BMD were measured. The percentage difference in the BMC
of (a) cortical bone showed consistent bone increase and (b) cancellous bone showing significant increase by Zn-TCP group. The BMDs of (c) cortical
bone showed no significant changes while the (d) cancellous bone BMD showed only the normal group having a significant difference.
doi:10.1371/journal.pone.0071821.g007
Zn-TCP in the Treatment of Osteoporotic Mice
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Discussion
In this study, the effect of biomimetic zinc containing tricalcium
phosphate (Zn-TCP) on the bone mineral content of the femur
bone was investigated in a zinc-deficient osteoporotic mice model.
This model was selected as the mice are at a young age and still
growing allowing the observation on the significance of zinc in
bone growth under osteoporotic conditions. Furthermore, Zn-
TCP and b-TCP were both implanted into the soft tissues near the
right femur of the osteoporotic mice. This surgical insertion was
made as a way to observe the localized therapeutic efficacy of Zn-
TCP and does not reflect on the clinical application of this system.
For clinical application, it is envision that the Zn-TCP could be
implanted near the peritoneal cavity as a more optimal
implantation site, which would reduce the impact on the patient’s
quality of life. Zn-TCP samples were produced by hydrothermally
converting calcium carbonate exoskeletons from foraminifera. This
allows the conversion to tricalcium phosphate while preservation
of the unique architectural structure of the exoskeletons. Forami-
nifera are abundant as fossils for the last 540 million years and can
be found in all marine environments but different species exists
depending on the local habitat. Foraminifera are single-celled
organisms with shells consisting of multi-layer inner chambers
commonly divided and added during its growth, which generate
the distinct porous chambers. The novelty in using foraminifera as a
carrier material is due to the interconnectivity of the uniform pores
the material naturally possess allowing a more consistent drug
loading and therefore a more predictable release rate. From the
XRD results, the crystallographic structure of Zn-TCP is closely
identical to b-TCP and from previous in vitro studies the zinc ions
are incorporated in place of the calcium ions [17]. SEM images
before implanting into the OVX mice also show zinc particles
embedded on the surface of Zn-TCP and the overall structure
remained structurally intact after being implanted for 4 weeks.
Since the zinc are incorporated into the lattice structure and on
the surface of the material, from the SEM images it is clear that
the pores are unfilled allowing the infiltration of cells and blood
once inside the body. Furthermore, this allows the extended option
of incorporating and loading the carrier material with other
stimulatory compounds that can address other therapeutic
response and needs. With any drug delivery system, its therapeutic
efficiency is highly dependent on the carrier’s ability to retain and
release the loaded pharmaceutical compounds. In vitro zinc release
in PBS buffer, which is calcium deficient and therefore simulates a
similar condition to osteoporosis, showed no zinc release in 7 days.
This suggests that the zinc incorporated in the TCP is relatively
stable and can provide a long-term release of zinc. In contrast, Zn-
TCP in acetate buffer (pH 4.5), which simulates an acidic
environment commonly associated with localized inflammatory
reaction after surgical incision, showed 70% zinc release in the
same 7-day period. This shows that zinc is relatively stable and
even in continuous acidic environment, zinc can still be retained in
the ZnTCP material. The biological environment will notably be
different and it is not expected that zinc from ZnTCP degradation
will be this fast as evident by the excised samples. Since Zn-TCP
has a low solubility rate, the release of zinc from calcium
phosphate material would be in a well-controlled and slow manner
[19]. In vitro zinc release was observed for 7 days as this provides a
general overview of the zinc release pattern and any extended
release studies would not correlate to the complex in vivo biological
setting. After the samples were implanted, macroscopic examina-
tion of the mice revealed no inflammatory reaction to the
implanted Zn-TCP. However serious muscle deterioration and
inflammatory response was observed in the zinc injected group,
which reached a toxic level after 2 weeks at which all the mice died
as a result. This is a classic example showing how a high-localized
concentration of pharmaceutics can elicit serious side effects while
a controlled and slow release of the same compound can avoid
such events. In this case, Zn-TCP delivery system is capable of
preventing the associated side effects of high zinc concentration in
the immediate area, which also reflects on the materials biological
tolerance. In the present study, the body weight of the mice were
observed during the experimental period as the differences in
increase body weight can be attributed to the pharmacological
effect of Zn-TCP. The weight of bones and muscles can account
for approximately 20 to 50% of the total body weight, which can
be use as a parameter that reflects on the bone generated. The
body weight from the normal and Zn-TCP group increased
significantly compared with sham, OVX and b-TCP after 4 weeks.
As such, the significant weight gained by the Zn-TCP group can
be attributed to the pharmacological effects of zinc released. A
close correlation can be made with the significantly higher plasma
zinc level found in the Zn-TCP group and the significant body
weight in the mice. Conversely, a lower plasma zinc level in the b-
TCP group was matched with no increase in body weight.
Interestingly the plasma zinc level in the OVX group is higher
compared with b-TCP. A hypothesis can be made that initially the
plasma zinc level in the OVX mice was low and to compensate the
zinc level, additional zinc was released from the bone to make-up
for the zinc deficiency. While this would increase the zinc level, it
will at the same time further deteriorate the conditions of the
osteoporotic bone. b-TCP samples would release calcium as the
material degrades therefore supplementing the body system with
calcium which might explain why zinc plasma level was lower in
this group. The results here further indicate that a sufficient level
of calcium and zinc in the blood plasma is necessary for body
growth. This suggests that lower zinc levels deactivate key enzymes
essential for growth [20]. The BMD level of the cortical and
cancellous bones reflects on the balance between absorption and
deposition of bone minerals which the results showed that only the
normal group had a significantly higher BMD compared with
sham, OVX, b-TCP and Zn-TCP group. The BMDs from these
groups remained unchanged during 4 weeks, which would suggest
the rate of absorption and deposition remained consistent
indicating that the effect of Zn-TCP was not sufficient enough
to increase the BMD of cortical and cancellous bone of the OVX
mice to the same level as the normal healthy mice group. In
contrast, the BMCs of the femurs were measured to evaluate the
local therapeutic effect of Zn-TCP. A plot of the BMC percentage
increase over 4 weeks showed significant cortical bone growth
from normal, b-TCP and Zn-TCP compared with OVX group.
Without the continual stimulatory effect on bone formation, the
osteoporotic condition will continue to resorb the cancellous bone.
Most interestingly and significant indication that Zn-TCP is
pharmacologically effective is the significant increase in the
percentage of cancellous bone growth in 4 weeks. Here it shows
that Zn-TCP was able to induce approximately 20% cancellous
bone growth compared with the 5% growth in normal mice. This
is as expected, since the normal group would have minimal growth
as the mice matures. Sham, OVX and b-TCP group all showed
decreased cancellous bone growth in the 4-week period, a trait
consistent with the OVX condition. The presented results indicate
that ZnTCP is capable of inducing localized cortical and
cancellous bone growth in osteoporotic mice and show potentials
for further investigation in larger animal models.
Zn-TCP in the Treatment of Osteoporotic Mice
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Conclusion
This study shows that Zn-TCP produced by hydrothermally
converting foraminifera is able to release zinc in a controlled and
slow manner over an extended period of time. The results indicate
that the Zn-TCP system is effective for localized therapy and that
long-term sustained zinc release from Zn-TCP may further
improve bone mineral density in Zn-deficient osteoporotic mice.
Based on these in vivo results, it can be conclude that the Zn-TCP
system is adequate and is therapeutically effective in inducing
localized cortical and cancellous bone growth while promoting
healthy body growth in osteoporotic mice.
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